Smaller Breast Implants Surge as GLP-1 Users Seek Volume, Not Size

More than 80 percent of patients consulting New York plastic surgeon Anna Steve, MD on breast enhancement are taking a GLP-1 medication — and most want restoration, not enlargement.

Dr. Steve, who specializes in small-volume breast enhancement and joined NewBeauty's first State of Aesthetics Roundtable in New York as a guest of implant maker Motiva, does not prescribe GLP-1s herself. "But probably more than 80 percent of my patients are on a GLP-1," she said. Most are not treating obesity. "I see patients who are mostly BMI 21 and less," she said, noting many take the medication for aesthetic reasons.

Why does GLP-1 weight loss change the breast?

The breast changes Dr. Steve observes after GLP-1 weight loss resemble postpartum changes, only earlier. For many women, they compound earlier losses. "I see patients who are in their perimenopausal years who maybe didn't have as much volume loss with pregnancy and breastfeeding, but they almost get a second hit with perimenopause, and then a third hit with GLP-1," she said.

That reframes the surgical goal. "It's not implants to be bigger; it's implants to restore the volume loss," Dr. Steve said.

How is the implant industry responding?

Manufacturers are moving the same direction. "We're seeing the shift towards smaller volume implants," said Malavika William, who leads global corporate communications and marketing at Establishment Labs, maker of Motiva implants. Two looks are gaining ground, she said: "The ballerina breast and the yoga breast is very much on trend."

In October, the FDA approved 28 additional sizes of smaller Motiva implants, down to 105 cc, across its SmoothSilk Round and Ergonomix styles. The Ergonomix implant is designed to move with the body for a more natural shape, according to the company. The approvals cap a year in which implant trends leaned softer and more proportional.

Patients now arrive with brand names. "Now you have patients coming in saying, 'I want the Motiva implant,'" said Beverly Hills, CA plastic surgeon Charles Galanis, MD, whose practice focuses on breast surgery and body contouring. "That wasn't something they were that specific about a few years ago." Some request Preservé, Motiva's minimally invasive approach.

Dr. Galanis connected the preference to demand for natural results. "Even in LA, it's more of a modest size," he said. "And I think that's where the Motiva implant has excelled."

What does the safety data show?

Capsular contracture — scar tissue tightening around an implant — ranks among the most common reasons for revision surgery. In Motiva's U.S. clinical study, the rate was 0.5 percent at five years among 451 primary augmentation patients, according to Establishment Labs.

Could augmentation become procedure-like rather than surgical?

Dr. Steve expects the shift to continue. "I think we're getting to the point where breast enhancement can be almost thought of more as a procedural or an injectable type of thing than a surgery," she said. Implant technology drives that shift, along with renewed interest in over-the-muscle placement designed to preserve tissue and ease recovery.

The trend extends beyond the chest. Austin, TX plastic surgeon Johnny Franco, MD said patients want a fit, athletic look from body procedures rather than dramatic size, and newer fat-based products have widened options for issues like implant rippling. Fat transfer remains another route for women seeking a modest change.

What should patients ask before booking?

Patients losing weight on a GLP-1 should ask their surgeon three questions: whether their weight has stabilized; whether volume alone will deliver the desired shape or a lift is also needed; and how the surgeon will coordinate with the doctor managing the medication. Dr. Steve prefers close collaboration with prescribers. "As a non-prescriber, I always like to collaborate with people who are sort of experts in their field," she said.

Patients should also ask what is inside their implant and why the surgeon chose it, especially when revising older devices. William called that transparency one of the biggest changes she has seen. "Ten years ago, you think back, and people had no idea what they were putting in their body," she said. "I feel like this evolution has really brought us closer to knowing those things and being more educated."

With FDA-cleared sizes now starting at 105 cc and GLP-1 use still climbing, restoration-driven augmentation looks set to keep gaining share over enlargement.